Breaking News

ideaPoint Launches Clinical Data Access Portal

By Kristin Brooks | January 3, 2014

Allows researchers to access sponsor clinical data

ideaPoint, Inc., a provider of partnering and collaboration systems for global enterprises, has launched a new portal designed to provide a secure system for researchers to request access to anonymized, patient-level clinical trial data provided by sponsor organizations ( Currently, the following study sponsors have committed to providing data through the site: Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi and ViiV Healthcare.
Researchers can select studies of interest from multiple sponsors across multiple disease areas and submit a research proposal through the portal, which are then reviewed by an Independent Review Panel that decides whether access should be granted. The panel reviews the proposed science, publication plans, conflicts of interest and the qualifications of the research team. The initiative envisions transitioning administration and review of future proposals to an independent third party as soon as possible. The site includes videos and guides on how to use the portal and submit a proposal. In addition, researchers can also submit inquiries to some study sponsors regarding the availability of data from studies not yet listed. Following approval, researchers are asked to sign a Data Sharing Agreement.
"The design and development of this user-friendly site is an outgrowth of our collaboration and partnering software. Supporting this need was a natural expansion of our work with life science, academic and non-profit organizations, and we are pleased to work with representatives from the sponsor organizations to achieve this milestone," said Scott Shaunessy, chief executive officer and founder of ideaPoint. "Our solution is highly configurable and will allow the functionality to expand as the initiative matures over time."

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research